Summary
Exenatide is a synthetic version of exendin-4, a peptide from Gila monster saliva that activates the GLP-1 receptor, the target of a gut hormone that boosts insulin after meals. It was the first drug in the class, FDA approved as twice daily Byetta in 2005 and as once weekly extended release Bydureon in 2012, for type 2 diabetes only. It lowers HbA1c (a measure of average blood sugar over about 3 months) by about 0.8 to 1.9 percentage points with 2 to 4 kg of weight loss, and in the 14,752 person EXSCEL trial it was safe but did not significantly reduce cardiovascular events (heart attacks, strokes, and cardiovascular deaths), so it has largely been superseded by liraglutide, dulaglutide, and semaglutide.
What is Exenatide?
Exenatide is a GLP-1 receptor agonist (synthetic 39 amino acid exendin-4, originally isolated from Gila monster saliva; twice daily and once weekly extended release forms). It is also known as Byetta, Bydureon, Bydureon BCise, exendin-4, synthetic exendin-4, AC2993.
How does it work?
Exenatide shares about 53% sequence identity with human GLP-1 but resists breakdown by the DPP-4 enzyme, giving a half life of about 2.4 hours for the immediate release form. It activates the GLP-1 receptor to increase glucose dependent insulin secretion, suppress inappropriately high glucagon, slow gastric emptying, and reduce food intake. The extended release form embeds exenatide in biodegradable microspheres that release it over about 10 weeks after each weekly injection.
| Cluster | GLP-1 and incretin agonists |
|---|---|
| Routes | Subcutaneous injection twice daily before meals (immediate release pen); Subcutaneous injection once weekly (extended release microsphere autoinjector) |
| Conditions studied | Type 2 diabetes; Cardiovascular risk reduction |
| Record | v2, draft, verified Sep 27, 2026 |
FDA-approved uses of Exenatide
Yes. Exenatide was the first GLP-1 receptor agonist (a drug that mimics the gut hormone GLP-1) approved by FDA, as twice daily Byetta in April 2005, followed by once weekly Bydureon in 2012 and Bydureon BCise in 2017. It is approved only to improve blood sugar in type 2 diabetes (Bydureon BCise also in children 10 and older). It is not approved for weight loss and has no obesity trial. [6] [7]
What does the evidence say about Exenatide?
Multiple randomized controlled trials in type 2 diabetes since 2004, plus a 14,752 person cardiovascular outcomes trial. Twice daily exenatide lowered HbA1c by 0.8 points versus a 0.1 point rise on placebo over 30 weeks in metformin treated patients (n = 336). Once weekly exenatide lowered HbA1c by 1.9 points over 30 weeks (DURATION-1, n = 295) but was less effective than liraglutide 1.8 mg (DURATION-6, n = 912). EXSCEL showed a hazard ratio of 0.91 for major adverse cardiovascular events (95% CI 0.83 to 1.00), noninferior but not superior to placebo.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 5 | 16553 |
| Human observational studies | 0 | n/a |
| Animal studies | 0 | n/a |
| All indexed studies | 5 | 16,553 |
Human evidence
DeFronzo 2005: 336 adults with type 2 diabetes on metformin, 30 weeks; HbA1c change minus 0.78 points (10 ug twice daily), minus 0.40 (5 ug) versus plus 0.08 on placebo; weight change minus 2.8 kg and minus 1.6 kg. DURATION-1: 295 adults, 30 weeks; exenatide 2 mg weekly lowered HbA1c 1.9 points versus 1.5 for 10 ug twice daily, with 77% versus 61% reaching HbA1c 7% or less; weight loss over 4 kg at 52 weeks in the extension. DURATION-6: 912 adults, 26 weeks; liraglutide 1.8 mg daily lowered HbA1c 1.48 points versus 1.28 for weekly exenatide, so exenatide failed noninferiority. EXSCEL: 14,752 adults with type 2 diabetes (73% with prior cardiovascular disease), median 3.2 years; primary outcome 11.4% versus 12.2% (hazard ratio 0.91, P = 0.06 for superiority).
Animal evidence
Exendin-4 was characterized in Gila monster venom and shown to be a potent GLP-1 receptor agonist in rodent models of glucose control. Rodent studies of the extended release form showed thyroid C cell tumors, the basis of the boxed warning on Bydureon; the twice daily form does not carry that warning.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes2005 PMID 15855572 | Randomized, triple blind, placebo controlled trial, 30 weeksn = 336 Adults with type 2 diabetes inadequately controlled on maximal metformin | HbA1c change minus 0.78 points (10 ug twice daily) and minus 0.40 (5 ug) versus plus 0.08 placebo; weight minus 2.8 kg and minus 1.6 kg | Evidence: Human RCT evidence |
| Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study (DURATION-1)2008 PMID 18782641 | Randomized, open label, noninferiority trial, 30 weeksn = 295 Adults with type 2 diabetes, drug naive or on oral agents | HbA1c change minus 1.9 points with 2 mg weekly versus minus 1.5 with 10 ug twice daily; 77% versus 61% reached HbA1c 7% or less | Evidence: Human RCT evidence |
| DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks2010 PMID 20215461 | Open label extension of a randomized trial, 52 weeks totaln = 258 Adults with type 2 diabetes continuing or switching to weekly exenatide | HbA1c reduction of 2.0 points maintained at 52 weeks; body weight reduced by more than 4 kg | Evidence: Human RCT evidence |
| Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6)2013 PMID 23141817 | Randomized, open label, parallel group trial, 26 weeksn = 912 Adults with type 2 diabetes on lifestyle and oral agents | HbA1c change minus 1.48 points with liraglutide 1.8 mg versus minus 1.28 with weekly exenatide; exenatide did not meet noninferiority | Evidence: Human RCT evidence |
| Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL)2017 PMID 28910237 | Randomized, double blind, placebo controlled cardiovascular outcomes trial, median 3.2 yearsn = 14,752 Adults with type 2 diabetes with or without prior cardiovascular disease | Major adverse cardiovascular events 11.4% versus 12.2% (hazard ratio 0.91, 95% CI 0.83 to 1.00); noninferior, not superior | Evidence: Human RCT evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Type 2 diabetes | Evidence: Human RCT evidence | First GLP-1 agonist approved (2005). |
| Cardiovascular risk reduction | Evidence: Human RCT evidence | EXSCEL (n = 14,752) showed cardiovascular safety but the 9% lower event rate was not statistically significant. |
Is Exenatide legal in the United States?
FDA and compounding status
FDA approved products (Byetta April 2005, Bydureon January 2012, Bydureon BCise October 2017) for type 2 diabetes. Because exenatide is a component of approved drugs, 503A pharmacies may compound it only for a documented patient specific need and may not produce essentially a copy of a marketed product. Exenatide was not part of the semaglutide and tirzepatide shortage era. Product presentations have narrowed over time; check DailyMed for what is currently marketed.
WADA status
Not WADA prohibited. Not named on the current prohibited list. Athletes should still confirm against the list in force for their season.
Regulatory timeline
- FDA
FDA approves Bydureon, once-weekly extended-release exenatide
FDA approved the extended-release, once-weekly formulation of exenatide (Bydureon) for type 2 diabetes after earlier complete response letters.
Regulatory: FDA approvedSource: Drugs@FDA: Bydureon (exenatide extended-release) NDA 022200 - FDA
FDA approves Byetta (exenatide), the first GLP-1 receptor agonist
FDA approved twice-daily exenatide injection (Byetta) as adjunctive therapy for type 2 diabetes, the first GLP-1 receptor agonist to reach the US market.
Regulatory: FDA approvedSource: Drugs@FDA: Byetta (exenatide) NDA 021773
Exenatide dosing: FDA label and trial doses
Doses below are quoted from the FDA label for its approved uses, plus the doses used in the pivotal trials where noted. The prescriber sets the dose; PeptideAgent does not recommend doses or protocols.
Byetta label and DeFronzo 2005: 5 ug subcutaneously twice daily within 60 minutes before morning and evening meals for 4 weeks, then 10 ug twice daily. Bydureon BCise label and DURATION-1: 2 mg subcutaneously once weekly. Both regimens are for type 2 diabetes in adults; Bydureon BCise is also labeled for children 10 and older.
Routes reported
| # | Route |
|---|---|
| 1 | Subcutaneous injection twice daily before meals (immediate release pen) |
| 2 | Subcutaneous injection once weekly (extended release microsphere autoinjector) |
What are the side effects and interactions of Exenatide?
Side effects
| # | Reported side effect |
|---|---|
| 1 | Nausea (most common, mild to moderate, decreases over time) |
| 2 | Vomiting and diarrhea |
| 3 | Injection site nodules with the extended release form (microsphere deposits) |
| 4 | Hypoglycemia when combined with sulfonylureas or insulin |
| 5 | Pancreatitis (rare; not increased in EXSCEL) |
| 6 | Acute kidney injury reported post marketing, usually with dehydration from vomiting |
| 7 | Boxed warning for thyroid C cell tumors on the extended release form only |
| 8 | Anti-exenatide antibodies in a substantial minority, occasionally reducing efficacy |
Interactions
| # | Interaction |
|---|---|
| 1 | Sulfonylureas and insulin: increased hypoglycemia risk, dose reduction usually needed |
| 2 | Oral medications that depend on threshold concentrations (for example antibiotics and oral contraceptives): label advises taking them at least 1 hour before exenatide because of delayed gastric emptying |
| 3 | Warfarin: post marketing reports of increased INR with bleeding; monitor |
| 4 | Other GLP-1 or GIP/GLP-1 agonists: not recommended in combination |
Contraindications
| # | Contraindication |
|---|---|
| 1 | Extended release form: personal or family history of medullary thyroid carcinoma or MEN2 |
| 2 | Prior serious hypersensitivity to exenatide |
| 3 | History of drug induced immune mediated thrombocytopenia from exenatide |
| 4 | Severe renal impairment or end stage renal disease (not recommended) |
| 5 | Not for type 1 diabetes or diabetic ketoacidosis |
How do people access Exenatide legally?
Typical cost: Byetta and Bydureon BCise list at roughly 800 to 1,000 USD per month. With commercial insurance a covered prescription is often 25 to 100 USD per month, and Medicare Part D covers exenatide for type 2 diabetes. No generic is available as of the last verified date, and many formularies now prefer newer GLP-1 agonists.
Verified access options
Step 1
Prescription from a licensed provider (in person or telehealth) filled at a retail or specialty pharmacy as Byetta or Bydureon BCise.
Step 2
Not available through compounding pharmacies or telehealth peptide clinics as a compounded product.
Step 3
Products labeled research use only are not lawful for human use.
Access paths are verified against public regulatory records and prescriber licensing. We never list unlicensed vendors.
Compare Exenatide
Frequently asked questions
Does exenatide work for weight loss?
Only modestly, and it is not approved for it. In the 30 week trial of twice daily exenatide with metformin, weight fell 2.8 kg at 10 ug and 1.6 kg at 5 ug versus placebo. In DURATION-1 the weekly form produced more than 4 kg of loss at 52 weeks. These effects are far below semaglutide 2.4 mg or tirzepatide, which is why exenatide is rarely chosen when weight is the goal. [1] [3]
What are the side effects of exenatide?
Nausea is the most common, affecting a large share of patients early and easing over weeks; vomiting and diarrhea also occur. The weekly form causes injection site nodules from its microspheres. Hypoglycemia is a risk with sulfonylureas or insulin. Rare reports include pancreatitis and acute kidney injury after dehydration from vomiting. Only the extended release form carries the boxed thyroid C cell warning. In EXSCEL, pancreatitis, pancreatic cancer, and medullary thyroid carcinoma rates did not differ from placebo. [1] [5] [7]
How is exenatide taken and what is the dose?
Byetta is injected under the skin twice daily within an hour before the morning and evening meals, starting at 5 ug and increasing to 10 ug after 4 weeks. Bydureon BCise is injected once weekly at 2 mg, at any time of day, using an autoinjector that must be shaken and used immediately. Neither should be injected after a meal. [2] [6] [7]
How much does exenatide cost?
Byetta and Bydureon BCise list at roughly 800 to 1,000 USD per month. Insured patients usually pay far less, often 25 to 100 USD with commercial coverage, and Medicare Part D covers it for type 2 diabetes. No generic exists as of the last verified date. Many insurers now steer patients to newer weekly GLP-1 agonists instead. Prices change often. [6]
Is exenatide banned by WADA?
No. GLP-1 receptor agonists including exenatide are not on the 2026 WADA Prohibited List or the 2027 list published in September 2026. Athletes should confirm any documentation requirements with their anti-doping organization. [8] [9]
Exenatide vs liraglutide: which is better?
Liraglutide. In the DURATION-6 head to head trial of 912 adults, liraglutide 1.8 mg daily lowered HbA1c by 1.48 points versus 1.28 for weekly exenatide, and weekly exenatide failed its noninferiority test. Liraglutide also reduced cardiovascular events in LEADER, while exenatide did not reach significance in EXSCEL (hazard ratio 0.91). Exenatide's weekly form does have less nausea than daily liraglutide. [4] [5]
Does exenatide protect the heart?
It is safe but the benefit was not proven. EXSCEL followed 14,752 people with type 2 diabetes for a median 3.2 years; major adverse cardiovascular events occurred in 11.4% on weekly exenatide versus 12.2% on placebo (hazard ratio 0.91, 95% CI 0.83 to 1.00). That met noninferiority but missed superiority (P = 0.06), so unlike liraglutide, dulaglutide, and semaglutide, exenatide carries no cardiovascular risk reduction indication. [5]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]DeFronzo RA et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005PubMed 15855572, 2005
- [2]Drucker DJ et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes (DURATION-1). Lancet 2008PubMed 18782641, 2008
- [3]Buse JB et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010PubMed 20215461, 2010
- [4]Buse JB et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6). Lancet 2013PubMed 23141817, 2013
- [5]Holman RR et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017 (EXSCEL)PubMed 28910237, 2017
- [6]FDA prescribing information for Byetta (exenatide) injection, via DailyMedFDA, 2025
- [7]FDA prescribing information for Bydureon BCise (exenatide extended-release) injectable suspension, via DailyMedFDA, 2025
- [8]WADA Prohibited ListWADA, 2026
- [9]WADA 2027 Prohibited List (published September 21, 2026, in force January 1, 2027)WADA, 2026
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 27). Exenatide: evidence, legality, and access. https://peptideagent.ai/peptides/exenatide- HTML link
<a href="https://peptideagent.ai/peptides/exenatide">Exenatide: evidence, legality, and access</a>, PeptideAgent, updated September 27, 2026.